Advertisement

Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma

Published:November 19, 2015DOI:https://doi.org/10.1016/j.gie.2015.11.016

      Background and Aims

      Photodynamic therapy (PDT) is a less-invasive salvage treatment option for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma. The objective of this study was to clarify the long-term outcomes and prognostic factors of salvage PDT.

      Methods

      One hundred thirteen consecutive patients treated in our institution with PDT for local failure limited to within T2 without any metastases after definitive CRT performed between 1998 and 2008 were retrospectively enrolled. The complete response rate, adverse events, and survival outcomes were assessed and prognostic factors were investigated using a multivariate analysis.

      Results

      The complete response rate was 58.4% (95% confidence interval [CI], 49.3%-67.5%). The progression-free survival (PFS) and the overall survival (OS) rates at 5 years after salvage PDT were 22.1% (95% CI, 14.3%-30.0%) and 35.9% (95% CI, 26.7%-45.1%). N0 before CRT was significantly associated with OS (hazard ratio [HR], 0.54; 95% CI, 0.33-0.91, P = .020), whereas the impact of T1 or T2 before CRT on PFS (HR, 0.63; 95% CI, 0.38-1.04, P = .068) and that of a longer period between CRT and PDT on OS (HR, 0.64; 95% CI, 0.39-1.05, P = .078) were marginal. The treatment-related death rate was 1.8%.

      Conclusions

      Salvage PDT was found to have a superior outcome and a satisfactory safety profile. An earlier clinical stage before CRT and a longer interval between CRT and PDT may be associated with a longer survival period.

      Abbreviations:

      CI (confidence interval), CRT (chemoradiotherapy), EPS (esophagus-preserved survival), ESCC (esophageal squamous cell carcinoma), HR (hazard ratio), OS (overall survival), PDT (photodynamic therapy), PFS (progression-free survival)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kato H.
        • Sato A.
        • Fukuda H.
        • et al.
        A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708).
        Jpn J Clin Oncol. 2009; 39: 638-643
        • Kato K.
        • Muro K.
        • Minashi K.
        • et al.
        Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
        Int J Radiat Oncol Biol Phys. 2011; 81: 684-690
        • Ohtsu A.
        • Boku N.
        • Muro K.
        • et al.
        Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
        J Clin Oncol. 1999; 17: 2915-2921
        • Miyata H.
        • Yamasaki M.
        • Takiguchi S.
        • et al.
        Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
        J Surg Oncol. 2009; 100: 442-446
        • Swisher S.G.
        • Wynn P.
        • Putnam J.B.
        • et al.
        Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy.
        J Thorac Cardiovasc Surg. 2002; 123: 175-183
        • Chao Y.K.
        • Chan S.C.
        • Chang H.K.
        • et al.
        Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus.
        Eur J Surg Oncol. 2009; 35: 289-294
        • Tachimori Y.
        • Kanamori N.
        • Uemura N.
        • et al.
        Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.
        J Thorac Cardiovasc Surg. 2009; 137: 49-54
        • Onozawa M.
        • Nihei K.
        • Ishikura S.
        • et al.
        Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus.
        Radiother Oncol. 2009; 92: 266-269
        • Yano T.
        • Muto M.
        • Minashi K.
        • et al.
        Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study.
        Int J Cancer. 2012; 131: 1228-1234
        • Yano T.
        • Muto M.
        • Minashi K.
        • et al.
        Long-term results of salvage photodynamic therapy for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma.
        Endoscopy. 2011; 43: 657-663
        • Sobin L.H.
        • Wittekind C.
        TNM classification of malignant tumors.
        6th ed. Wiley-Liss, New York2002
        • Sibille A.
        • Lambert R.
        • Souquet J.C.
        • et al.
        Long-term survival after photodynamic therapy for esophageal cancer.
        Gastroenterology. 1995; 108: 337-344
        • Owaki T.
        • Matsumoto M.
        • Okumura H.
        • et al.
        Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma.
        Am J Surg. 2012; 203: 191-197
        • Clopper C.J.
        • Pearson E.S.
        The use of confidence or fiducial limits illustrated in the case of the binomial.
        Biometrika. 1934; 26: 404-413
        • Minsky B.D.
        • Pajak T.F.
        • Ginsberg R.J.
        • et al.
        INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
        J Clin Oncol. 2002; 20: 1167-1174
        • Tomimaru Y.
        • Yano M.
        • Takachi K.
        • et al.
        Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy.
        J Surg Oncol. 2006; 93: 422-428
        • Yoo C.
        • Park J.H.
        • Yoon D.H.
        • et al.
        Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.
        Ann Thorac Surg. 2012; 94: 1862-1868
        • Tahara M.
        • Ohtsu A.
        • Hironaka S.
        • et al.
        Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
        Jpn J Clin Oncol. 2005; 35: 316-323
        • Griffin J.M.
        • Reed C.E.
        • Denlinger C.E.
        Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
        Ann Thorac Surg. 2012; 93 (discussion 1860): 1855-1859
        • Kalha I.
        • Kaw M.
        • Fukami N.
        • et al.
        The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy.
        Cancer. 2004; 101: 940-947
        • Zhang X.
        • Watson D.I.
        • Lally C.
        • et al.
        Endoscopic ultrasound for preoperative staging of esophageal carcinoma.
        Surg Endosc. 2005; 19: 1618-1621
        • Tu C.H.
        • Muto M.
        • Horimatsu T.
        • et al.
        Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
        Dis Esophagus. 2011; 24: 274-278
        • Hattori S.
        • Muto M.
        • Ohtsu A.
        • et al.
        EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer.
        Gastrointest Endosc. 2003; 58: 65-70
        • Yano T.
        • Muto M.
        • Hattori S.
        • et al.
        Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
        Endoscopy. 2008; 40: 717-721
        • Jin J.
        • Xu X.
        • Wang F.
        • et al.
        Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
        J Thorac Oncol. 2009; 4: 1017-1021
        • Kato K.
        • Tahara M.
        • Hironaka S.
        • et al.
        A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.
        Cancer Chemother Pharmacol. 2011; 67: 1265-1272
        • Muro K.
        • Hamaguchi T.
        • Ohtsu A.
        • et al.
        A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
        Ann Oncol. 2004; 15: 955-959
        • Nonoshita T.
        • Sasaki T.
        • Hirata H.
        • et al.
        High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer.
        Radiat Med. 2007; 25: 373-377
        • Sharan K.
        • Fernandes D.J.
        • Prakash Saxena P.U.
        • et al.
        Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer.
        J Cancer Res Ther. 2014; 10: 337-341